請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/65371
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 鍾國彪(Kuo-Piao Chung) | |
dc.contributor.author | Yi-Chiu Ou | en |
dc.contributor.author | 歐怡秋 | zh_TW |
dc.date.accessioned | 2021-06-16T23:39:08Z | - |
dc.date.available | 2020-03-12 | |
dc.date.copyright | 2020-03-12 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-02-19 | |
dc.identifier.citation | 丁雅嵐(2010)‧家屬與癌末病患對入住安寧病房之決策過程‧國防醫學院護理研究所,台北市。
吳美幸(2009)‧家屬對病人入住安寧病房的決策經驗‧長榮大學護理學研究所,台南市。 吳麗珍、黃惠滿、李浩銑 (2014)‧方便取樣和立意取樣之比較‧護理雜誌,61(3),105-111。doi: 10.6224/jn.61.3.105 李欣慈、趙詩瑾、廖珍娟、周桂如(2005)‧腫瘤治療新趨勢:標靶治療‧腫瘤護理雜誌,5(2),29-42。 林玉芬、鄭吉元、王昭慧、張文震、陳麗娟、李淑慧(2018)‧淺談癌症免疫治療‧腫瘤護理雜誌,18(1),5-11。doi: 10.3966/168395442018061801001 邱秀渝(2016)‧癌症病人的治療決策過程。護理雜誌,63(5),12-18。doi: 10.6224/jn.63.5.12 姜紹青(2006)‧抗癌化學藥物治療原則簡介‧腫瘤護理雜誌,6(1),1-8。 唐婉如、方俊凱、莊永毓 (2013)‧癌症病情告知教育‧台灣醫學, 17(2),141-148。doi: 10.6320/fjm.2013.17(2).06 國家衛生研究院(2018,2018年12月17日)‧癌症診療品質認證作業計畫認證簡介‧取自 http://accredit.nhri.org.tw/intro/ 康鈺玫、胡育文(2016)‧免疫治療與放射線治療‧臨床醫學月刊,78(5),243-246。doi: 10.6666/ClinMed.2016.78.5.013 許育瑋(2017)‧癌症治療的新趨勢-免疫治療‧嘉基藥訊(127),1-3。 郭玉霞、劉世閔、王為國、黃世奇、何明軒、洪梓榆(2009)‧質性研究資料分析:NVivo 8活用寶典‧臺北:高等教育出版。 郭淑娥、唐秀治、高振益、唐婉如(2008)‧探討影響醫師對乳癌病人病情告知之研究‧安寧療護雜誌,13(3),265-281。doi: 10.6537/tjhpc.2008.13(3).1 陳佑瑋(2019)‧末期癌症病患的薪資所得與選擇安寧照護的關聯‧國立中央大學產業經濟研究所,桃園縣。 陳怡婷(2003)‧家庭系統面臨親人重病事件的運作與轉變--以進入安寧病房的家庭為例‧國立彰化師範大學輔導與諮商系,彰化縣。 陳雪姝、謝秋萍、李幸諭、蔡瓊玉、李哲瑋(2015)‧安寧療護使用天數對末期病人醫療資源耗用之影響‧台灣公共衛生雜誌,34(4),413-423。doi: 10.6288/tjph201534104039 臺灣癌症登記中心(2017)‧存活分析‧取自http://tcr.cph.ntu.edu.tw/main.php?Page=A5B3 劉世閔、曾世豐(2013)‧NVivo10在臺灣質性研究中的位置與批判‧臺灣教育評論月刊,2(4),65-71。 劉世閔、曾世豐、鍾明倫(2017)‧NVivo 11與網路質性研究方法論‧台北市:五南圖書出版股份有限公司。 衛生福利部(2019,2019年8月28日)‧107年死因統計結果分析‧取自 https://dep.mohw.gov.tw/DOS/cp-4472-48034-113.html 衛生福利部國民健康署(2018)‧105年癌症登記報告‧取自 https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=269&pid=10227 衛生福利部國民健康署(2019)‧安寧療護‧取自https://www.hpa.gov.tw/Pages/List.aspx?nodeid=210 鄭舒帆、鄭高珍(2018)‧肺癌的免疫治療‧內科學誌,29(3),153-159。doi: 10.6314/jimt.201806_29(3).05 謝邦昌、林恆慶、陳正怡、丁台怡(2018)‧癌症負擔研究‧Journal of Data Analysis, 13(2),63-76。doi: 10.6338/jda.201804_13(2).0004 謝秋菊、李麗雲、周繡玲、簡淑慧(2012)‧探討推動安寧療護之障礙因子及其應對策略建議‧腫瘤護理雜誌,12(2),51-59。 謝德熾、陳立奇(2010)‧抗血管新生與節拍式化療:嶄新的癌化學治療概念。台灣醫學,14(6),696-702。doi: 10.6320/fjm.2010. 14(6). 13 Akabayashi, A., Fetters, M. D., & Elwyn, T. S. (1999). Family consent, communication, and advance directives for cancer disclosure: a Japanese case and discussion. J Med Ethics, 25(4), 296-301. doi:10.1136/jme.25.4.296 Barrett, B. (2012). Evidence, values, guidelines and rational decision-making. J Gen Intern Med, 27(2), 238-240. doi:10.1007/s11606-011-1903-6 Baszanger, I. (2012). One more chemo or one too many? Defining the limits of treatment and innovation in medical oncology. Social Science & Medicine, 75(5), 864-872. doi:10.1016/j.socscimed.2012.03.023 Behl, D., & Jatoi, A. (2010). What Do Oncologists Say about Chemotherapy at the Very End of Life? Results from a Semiqualitative Survey. Journal of Palliative Medicine, 13(7), 831-835. doi:10.1089/jpm.2009.0414 Benthien, K. S., Adsersen, M., Petersen, M. A., Vadstrup, E. S., Sjogren, P., & Groenvold, M. (2018). Is specialized palliative cancer care associated with use of antineoplastic treatment at the end of life? A population-based cohort study. Palliative Medicine, 32(9), 1509-1517. doi:10.1177/0269216318786393 Bluhm, M., Connell, C. M., De Vries, R. G., Janz, N. K., Bickel, K. E., & Silveira, M. J. (2016). Paradox of Prescribing Late Chemotherapy: Oncologists Explain. Journal of Oncology Practice, 12(12), e1006-e1015. Retrieved from http://search.ebscohost.com/login.aspx?direct=true&db=mdc&AN=27650843&site=ehost-live&scope=site Bluhm, M., Connell, C. M., Janz, N., Bickel, K., DeVries, R., & Silveira, M. (2017). Oncologists' End of Life Treatment Decisions. J Appl Gerontol, 36(4), 416-440. doi:10.1177/0733464815595510 Brandao, C., & Miguez, J. (2017). Using NVivo to assess a program of goal-corrected empathic attunement skills: a case study in the context of higher education. Universal Access in the Information Society, 16(4), 863-876. doi:10.1007/s10209-016-0476-x Browner, I., & Carducci, M. A. (2005). Palliative chemotherapy: Historical perspective, applications, and controversies. Seminars in Oncology, 32(2), 145-155. doi:https://doi.org/10.1053/j.seminoncol.2004.11.014 Buiting, H. M., Rurup, M. L., Wijsbek, H., van Zuylen, L., & den Hartogh, G. (2011). Understanding provision of chemotherapy to patients with end stage cancer: qualitative interview study. BMJ Supportive & Palliative Care, 1(1), 33-41. doi:10.1136/bmj.d1933 Buiting, H. M., Terpstra, W., Dalhuisen, F., Gunnink-Boonstra, N., Sonke, G. S., & den Hartogh, G. (2013). The Facilitating Role of Chemotherapy in the Palliative Phase of Cancer: Qualitative Interviews with Advanced Cancer Patients. Plos One, 8(11). doi:10.1371/journal.pone.0077959 Caires-Lima, R., Cayres, K., Protasio, B., Caires, I., Andrade, J., Rocha, L., . . . Mak, M. P. (2018). Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1. Ecancermedicalscience, 12. doi:10.3332/ecancer.2018.831 Chen, S. J., Kung, P. T., Huang, K. H., Wang, Y. H., & Tsai, W. C. (2015). Characteristics of the Delayed or Refusal Therapy in Breast Cancer Patients: A Longitudinal Population-Based Study in Taiwan. Plos One, 10(6), e0131305. doi:10.1371/journal.pone.0131305 Chiang, T. Y., Wang, C. H., Lin, Y. F., Chou, S. L., Wang, C. T., Juang, H. T., . . . Lin, M. H. (2015). Factors related to treatment refusal in Taiwanese cancer patients. Asian Pac J Cancer Prev, 16(8), 3153-3157. doi:10.7314/apjcp.2015.16.8.3153 Chiang, T. Y., Wang, C. H., Lin, Y. F., You, J. F., Chen, J. S., & Chen, S. C. (2018). Colorectal cancer in Taiwan: A case-control retrospective analysis of the impact of a case management programme on refusal and discontinuation of treatment. J Adv Nurs, 74(2), 395-406. doi:10.1111/jan.13443 Choi, Y., Keam, B., Kim, T. M., Lee, S. H., Kim, D. W., & Heo, D. S. (2015). Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute. Cancer Res Treat, 47(4), 555-563. doi:10.4143/crt.2014.200 Cinausero, M., Gerratana, L., De Carlo, E., Iacono, D., Bonotto, M., Fanotto, V., . . . Puglisi, F. (2018). Determinants of Last-line Treatment in Metastatic Breast Cancer. Clinical Breast Cancer, 18(3), 205-213. doi:10.1016/j.clbc.2017.07.008 Clarke, G., Johnston, S., Corrie, P., Kuhn, I., & Barclay, S. (2015). Withdrawal of anticancer therapy in advanced disease: a systematic literature review. Bmc Cancer, 15. doi:10.1186/s12885-015-1862-0 Collins, A., Sundararajan, V., Burchell, J., Millar, J., McLachlan, S. A., Krishnasamy, M., . . . Philip, J. (2018). Transition Points for the Routine Integration of Palliative Care in Patients With Advanced Cancer. J Pain Symptom Manage, 56(2), 185-194. doi:10.1016/j.jpainsymman.2018.03.022 Colomer, R., Hall, P., Szkultecka-Debek, M., Bondi, R. C., Flinois, A., Auziere, S., & Le Cleac'h, J. Y. (2018). Real-world treatment in patients with HER2+metastatic breast cancer. Breast Cancer Research and Treatment, 168(1), 197-205. doi:10.1007/s10549-017-4567-z Cullen, M. H., Billingham, L. J., Woodroffe, C. M., Chetiyawardana, A. D., Gower, N. H., Joshi, R., . . . Souhami, R. L. (1999). Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol, 17(10), 3188-3194. doi:10.1200/jco.1999.17.10.3188 Earle, C. C., Neville, B. A., Landrum, M. B., Ayanian, J. Z., Block, S. D., & Weeks, J. C. (2004). Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol, 22(2), 315-321. doi:10.1200/JCO.2004.08.136 Earle, C. C., Neville, B. A., Landrum, M. B., Souza, J. M., Weeks, J. C., Block, S. D., . . . Ayanian, J. Z. (2005). Evaluating claims-based indicators of the intensity of end-of-life cancer care. Int J Qual Health Care, 17(6), 505-509. doi:10.1093/intqhc/mzi061 Earle, C. C., Park, E. R., Lai, B., Weeks, J. C., Ayanian, J. Z., & Block, S. (2003). Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol, 21(6), 1133-1138. doi:10.1200/JCO.2003.03.059 Ellis, P. A., Smith, I. E., Hardy, J. R., Nicolson, M. C., Talbot, D. C., Ashley, S. E., & Priest, K. (1995). Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer, 71(2), 366-370. doi:10.1038/bjc.1995.74 Entwistle, V. A., & Watt, I. S. (2006). Patient involvement in treatment decision-making: the case for a broader conceptual framework. Patient Educ Couns, 63(3), 268-278. doi:10.1016/j.pec.2006.05.002 Fallowfield, L. J., Jenkins, V. A., & Beveridge, H. A. (2002). Truth may hurt but deceit hurts more: communication in palliative care. Palliat Med, 16(4), 297-303. doi:10.1191/0269216302pm575oa Fujimori, M., Akechi, T., Morita, T., Inagaki, M., Akizuki, N., Sakano, Y., & Uchitomi, Y. (2007). Preferences of cancer patients regarding the disclosure of bad news. Psychooncology, 16(6), 573-581. doi:10.1002/pon.1093 Ghavamzadeh, A., & Bahar, B. (1997). Communication with the cancer patient in Iran. Information and truth. Ann N Y Acad Sci, 809, 261-265. doi:10.1111/j.1749-6632.1997.tb48089.x Gibbs, G. R. (2010). 質性資料的分析 (吳佳綺, Trans.). Grendarova, P., Sinnarajah, A., Trotter, T., Card, C., & Wu, J. S. (2015). Variations in intensity of end-of-life cancer therapy by cancer type at a Canadian tertiary cancer centre between 2003 and 2010. Support Care Cancer, 23(10), 3059-3067. doi:10.1007/s00520-015-2676-y Hong, J. H., Rho, S. Y., & Hong, Y. S. (2013). Trends in the Aggressiveness of End-of-Life Care for Advanced Stomach Cancer Patients. Cancer Res Treat, 45(4), 270-275. doi:10.4143/crt.2013.45.4.270 Houghton, C., Murphy, K., Meehan, B., Thomas, J., Brooker, D., & Casey, D. (2017). From screening to synthesis: using nvivo to enhance transparency in qualitative evidence synthesis. Journal of Clinical Nursing, 26(5-6), 873-881. doi:10.1111/jocn.13443 Hsieh, H. F., & Shannon, S. E. (2005). Three approaches to qualitative content analysis. Qual Health Res, 15(9), 1277-1288. doi:10.1177/1049732305276687 Huang, H. L., Kung, P. T., Chiu, C. F., Wang, Y. H., & Tsai, W. C. (2014). Factors associated with lung cancer patients refusing treatment and their survival: a national cohort study under a universal health insurance in Taiwan. Plos One, 9(7), e101731. doi:10.1371/journal.pone.0101731 Institute of Medicine and National Research Council, C. o. L. S., Institute of Medicine, National Cancer Policy Board. (1999). Ensuring Quality Cancer Care (M. H. Joseph V. Simone Ed.): National Academies Press. Jorgensen, M. L., Young, J. M., & Solomon, M. J. (2013). Adjuvant chemotherapy for colorectal cancer: Age differences in factors influencing patients' treatment decisions. Patient Preference and Adherence, 7, 827-834. doi:10.2147/PPA.S50970 Kawakami, S., Arai, G., Ueda, K., Murai, Y., Yokomichi, H., Aoshima, M., & Takagi, K. (2001). Physician's attitudes towards disclosure of cancer diagnosis to elderly patients: a report from Tokyo, Japan. Arch Gerontol Geriatr, 33(1), 29-36. doi:10.1016/s0167-4943(01)00099-1 Keam, B., Oh, D. Y., Lee, S. H., Kim, D. W., Kim, M. R., Im, S. A., . . . Heo, D. S. (2008). Aggressiveness of cancer-care near the end-of-life in Korea. Japanese Journal of Clinical Oncology, 38(5), 381-386. doi:10.1093/jjco/hyn031 Keam, B., Yun, Y. H., Heo, D. S., Park, B. W., Cho, C. H., Kim, S., . . . Chun, M. (2013). The attitudes of Korean cancer patients, family caregivers, oncologists, and members of the general public toward advance directives. Supportive Care in Cancer, 21(5), 1437-1444. doi:10.1007/s00520-012-1689-z Kim, S. H., Shin, D. W., Kim, S. Y., Yang, H. K., Nam, E., Jho, H. J., . . . Park, J. H. (2016). Terminal Versus Advanced Cancer: Do the General Population and Health Care Professionals Share a Common Language? Cancer Res Treat, 48(2), 759-767. doi:10.4143/crt.2015.124 Kumar, M., Goyal, S., Singh, K., Pandit, S., Sharma, D., Verma, A. K., . . . Bhatnagar, S. (2009). Breaking bad news issues: a survey among radiation oncologists. Indian J Palliat Care, 15(1), 61-66. doi:10.4103/0973-1075.53533 Lakeman, R. (2008). Qualitative Data Analysis with NVivo. Journal of Psychiatric and Mental Health Nursing, 15(10), 868-868. doi:10.1111/j.1365-2850.2008.01257.x Langton, J. M., Srasuebkul, P., Reeve, R., Parkinson, B., Gu, Y., Buckley, N. A., . . . Pearson, S. A. (2015). Resource use, costs and quality of end-of-life care: observations in a cohort of elderly Australian cancer decedents. Implement Sci, 10, 25. doi:10.1186/s13012-014-0148-2 Leong, M., Shah, M., & Smith, T. J. (2016). How to Avoid Late Chemotherapy. J Oncol Pract, 12(12), 1208-1210. doi:10.1200/JOP.2016.017137 Liu, C. N., & Yang, M. C. (2002). National Health Insurance expenditure for adult beneficiaries in Taiwan in their last year of life. Journal of the Formosan Medical Association, 101(8), 552-559. Retrieved from <Go to ISI>://WOS:000179030500004 Liu, C. Y., Chen, W. T., Kung, P. T., Chiu, C. F., Wang, Y. H., Shieh, S. H., & Tsai, W. C. (2014). Characteristics, survival, and related factors of newly diagnosed colorectal cancer patients refusing cancer treatments under a universal health insurance program. Bmc Cancer, 14, 446. doi:10.1186/1471-2407-14-446 Liu, L. N., Chen, C. H., Liu, T. W., Lin, Y. C., Lee, S. C. K., & Tang, S. T. (2015). Preferences for Aggressive End-of-life Care and Their Determinants Among Taiwanese Terminally Ill Cancer Patients. Cancer Nursing, 38(3), E9-E18. doi:10.1097/NCC.0000000000000155 Mack, J. W., Chen, K., Boscoe, F. P., Gesten, F. C., Roohan, P. J., Schymura, M. J., & Schrag, D. (2015). High Intensity of End-of-Life Care Among Adolescent and Young Adult Cancer Patients in the New York State Medicaid Program. Med Care, 53(12), 1018-1026. doi:10.1097/mlr.0000000000000437 Mack, J. W., Chen, L. H., Cannavale, K., Sattayapiwat, O., Cooper, R. M., & Chao, C. R. (2015). End-of-Life Care Intensity Among Adolescent and Young Adult Patients With Cancer in Kaiser Permanente Southern California. JAMA Oncol, 1(5), 592-600. doi:10.1001/jamaoncol.2015.1953 May, P., & Figgins, B. (2016). Oral anticancer therapy: a comprehensive assessment of patient perceptions and challenges. Journal of Community and Supportive Oncology, 14(3), 112-116. doi:10.12788/jcso.0226 Mitra, A. K., Agrahari, V., Mandal, A., Cholkar, K., Natarajan, C., Shah, S., . . . Pal, D. (2015). Novel delivery approaches for cancer therapeutics. J Control Release, 219, 248-268. doi:10.1016/j.jconrel.2015.09.067 Mystakidou, K., Parpa, E., Tsilila, E., Katsouda, E., & Vlahos, L. (2004). Cancer information disclosure in different cultural contexts. Support Care Cancer, 12(3), 147-154. doi:10.1007/s00520-003-0552-7 Novack, D. H., Plumer, R., Smith, R. L., Ochitill, H., Morrow, G. R., & Bennett, J. M. (1979). Changes in physicians' attitudes toward telling the cancer patient. JAMA, 241(9), 897-900. Retrieved from https://jamanetwork.com/journals/jama/articlepdf/363733/jama_241_9_012.pdf Odejide, O. O., Cronin, A. M., Condron, N. B., Fletcher, S. A., Earle, C. C., Tulsky, J. A., & Abel, G. A. (2016). Barriers to Quality End-of-Life Care for Patients With Blood Cancers. Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology, 34(26), 3126-3132. doi:10.1200/JCO.2016.67.8177 Peppercorn, J. M., Smith, T. J., Helft, P. R., Debono, D. J., Berry, S. R., Wollins, D. S., . . . Schnipper, L. E. (2011). American society of clinical oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol, 29(6), 755-760. doi:10.1200/jco.2010.33.1744 Rainbird, K., Perkins, J., Sanson-Fisher, R., Rolfe, I., & Anseline, P. (2009). The needs of patients with advanced, incurable cancer. Br J Cancer, 101(5), 759-764. doi:10.1038/sj.bjc.6605235 Romo, R. D., Wallhagen, M. I., & Smith, A. K. (2016). Viewing Hospice Decision Making as a Process. American Journal of Hospice & Palliative Medicine, 33(5), 503-510. doi:10.1177/1049909115569592 Rutten, L. J., Arora, N. K., Bakos, A. D., Aziz, N., & Rowland, J. (2005). Information needs and sources of information among cancer patients: a systematic review of research (1980-2003). Patient Educ Couns, 57(3), 250-261. doi:10.1016/j.pec.2004.06.006 Schildmann, J., Tan, J., Salloch, S., & Vollmann, J. (2013). 'Well, I think there is great variation...': a qualitative study of oncologists' experiences and views regarding medical criteria and other factors relevant to treatment decisions in advanced cancer. The Oncologist, 18(1), 90-96. doi:10.1634/theoncologist.2012-0206 Sheng, J., Zhang, Y.-X., He, X.-B., Fang, W.-F., Yang, Y.-P., Lin, G.-N., . . . Zhang, L. (2017). Chemotherapy Near the End of Life for Chinese Patients with Solid Malignancies. Oncologist, 22(1), 53-60. doi:10.1634/theoncologist.2016-0013 Sheng, J., Zhang, Y. X., He, X. B., Fang, W. F., Yang, Y. P., Lin, G. N., . . . Zhang, L. (2017). Chemotherapy Near the End of Life for Chinese Patients with Solid Malignancies. Oncologist, 22(1), 53-60. doi:10.1634/theoncologist.2016-0013 Smith, T. J., Temin, S., Alesi, E. R., Abernethy, A. P., Balboni, T. A., Basch, E. M., . . . Von Roenn, J. H. (2012). American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol, 30(8), 880-887. doi:10.1200/jco.2011.38.5161 Tariman, J. D., Doorenbos, A., Schepp, K. G., Singhal, S., & Berry, D. L. (2014). Information Needs Priorities in Patients Diagnosed With Cancer: A Systematic Review. J Adv Pract Oncol, 2014(5), 115-122. Taylor, J. S., Brown, A. J., Prescott, L. S., Sun, C. C., Ramondetta, L. M., & Bodurka, D. C. (2016). Dying well: How equal is end of life care among gynecologic oncology patients? Gynecol Oncol, 140(2), 295-300. doi:10.1016/j.ygyno.2015.12.012 Thomsen, O. O., Wulff, H. R., Martin, A., & Singer, P. A. (1993). What do gastroenterologists in Europe tell cancer patients? Lancet, 341(8843), 473-476. doi:10.1016/0140-6736(93)90218-6 Tsai, H.-Y., Chung, K.-P., & Kuo, R. N.-C. (2018). Impact of Targeted Therapy on the Quality of End-of-Life Care for Patients With NoneSmall-Cell Lung Cancer: A Population-Based Study in Taiwan. Journal of Pain and Symptom Management, 55(3), 798-+. doi:10.1016/j.jpainsymman.2017.10.009 Uchitomi, Y., & Yamawaki, S. (1997). Truth-telling practice in cancer care in Japan. Ann N Y Acad Sci, 809, 290-299. doi:10.1111/j.1749-6632.1997.tb48092.x Umezawa, S., Fujimori, M., Matsushima, E., Kinoshita, H., & Uchitomi, Y. (2015). Preferences of advanced cancer patients for communication on anticancer treatment cessation and the transition to palliative care. Cancer, 121(23), 4240-4249. doi:10.1002/cncr.29635 Wang, S. Y., Chen, C. H., Chen, Y. S., & Huang, H. L. (2004). The attitude toward truth telling of cancer in Taiwan. J Psychosom Res, 57(1), 53-58. doi:10.1016/s0022-3999(03)00566-x Weeks, J. C., Catalano, P. J., Cronin, A., Finkelman, M. D., Mack, J. W., Keating, N. L., & Schrag, D. (2012). Patients' expectations about effects of chemotherapy for advanced cancer. New England Journal of Medicine, 367(17), 1616-1625. doi:10.1056/NEJMoa1204410 WHO. (2017). Media centre: Cancer. Retrieved from http://www.who.int/mediacentre/factsheets/fs297/en/ Wu, C. C., Hsu, T. W., Chang, C. M., Lee, C. H., Huang, C. Y., & Lee, C. C. (2016). Palliative Chemotherapy Affects Aggressiveness of End-of-Life Care. Oncologist, 21(6), 771-777. doi:10.1634/theoncologist.2015-0445 Zamawe, F. C. (2015). The Implication of Using NVivo Software in Qualitative Data Analysis: Evidence-Based Reflections. Malawi Medical Journal, 27(1), 13-15. doi:10.4314/mmj.v27i1.4 Zdenkowski, N., Cavenagh, J., Ku, Y. C., Bisquera, A., & Bonaventura, A. (2013). Administration of chemotherapy with palliative intent in the last 30 days of life: the balance between palliation and chemotherapy. Intern Med J, 43(11), 1191-1198. doi:10.1111/imj.12245 Zijlstra, M., van der Geest, L. G. M., van Laarhoven, H. W. M., Lemmens, V. E. P. P., van de Poll-Franse, L. V., & Raijmakers, N. J. H. (2018). Patient characteristics and treatment considerations in pancreatic cancer: a population based study in the Netherlands. Acta Oncologica, 57(9), 1185-1191. doi:10.1080/0284186x.2018.1470330 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/65371 | - |
dc.description.abstract | 背景:對於不可根治的晚期癌症而言,抗癌治療因可延長生命,故仍是相當重要的。然而,對於末期、遠端轉移或復發的癌症而言,抗癌治療並不能顯著地延長存活,此時,以提升末期生命品質為目標的安寧療護,便是不可治癒癌症的首要處置選項。研究指出,多數往生者並未接受過相關服務,即便接受安寧療護者,可能在接受安寧療護後數週或甚至數日內死亡,顯示接受的時機過晚。由此可知,終止抗癌治療的決策在臨床實務上是相當困難的,而持續抗癌治療不止影響癌末病人採取積極醫療的態度,亦可能造成個體的壓力及健康體系醫療資源的耗費。
目的:從醫護團隊及病人或家屬觀點,探索癌症病人終止抗癌治療及接受安寧療護的決策。 方法:本研究採用質性方法,從臺灣東部某區域教學醫院之消化道癌症、乳癌、胸腔癌專科醫療團隊的病人與家屬,以及主責醫療團隊成員,採半結構式進行個人深度訪談,並運用NVivo 12.0 Plus質性分析軟體協助處理訪談資料與分析。 結果:本研究共計訪談主責醫療團隊成員11人,病人或家屬7人,病人診斷包括:大腸直腸癌、乳癌及肺癌。終止抗癌治療決策的因素與時機受病人年紀、不同癌別特性影響,「抗癌療效與生理健康狀態」為最主要因素,然而「主觀感受或心理因素」及「家庭社會或經濟支持」皆有相當的影響性。終止抗癌治療的決策過程包括:「主治醫師與病情告知內容與技巧」、「病人自主想法傳達」、「非醫師職類發揮輔助角色」、「尋求共識」,以及醫療端與病家端在面對相關情境各自的「因應作法」。完備的病情告知及團隊完善發揮輔助角色,有助於終止抗癌的決策。安寧療護的介入與接受,前提須醫療與病家皆接受抗癌治療為無效、無意義或死亡之必然性。選擇安寧療護的需求在於症狀處理、促進舒適、心理及靈性支持。早期介入緩和照護,有助於提升晚期癌症病人生活品質,然而現階段在急性病房推展,仍有實行的困境。 結論:本研究初步了解國內晚期癌症病人終止抗癌治療與接受安寧療護的決策,包括病人、家屬與醫療團隊的觀點。研究結果可提供於政策面、實務面推行之參考,並可作為後續研究之基礎依據。 | zh_TW |
dc.description.abstract | Background: Anticancer therapy plays a big role in defeating cancer, even in already declared incurable and advanced cases. For terminal, distal metastatic or recurrent cancer patients, however, anticancer therapy cannot prolong life significantly. Hospice, therefore, is often offered as the first option under these incurable situations to improve patients’ end-of-life quality. Studies revealed that most decedents had not received any hospice service; moreover, a majority of hospice patients died within weeks, even only several days after enrolling, suggested too late to be anticipated. Accordingly, clinical decision-making concerning the withhold of anticancer therapy is difficult, and continuous anticancer therapy probably not only affect the aggressiveness of end-of-life care, but also impose considerable pressure on individuals and financially constrain their healthcare systems.
Purpose: The purpose of this study is to explore process of decision-making on withholding anticancer therapy and accepting hospice care in cancer patients, from views of members in multidisciplinary care teams and patients or their families. Method: Qualitative method was adopted for this study. The semi-structured in-depth interview were separately adopted for the healthcare providers and patients or their families in gastrointestinal cancer, breast cancer and thoracic cancer multidisciplinary care team in one regional teaching hospital in eastern Taiwan. The CAQDAs, NVivo 12.0 Plus, was applied to manage and analyze the interviewed data in this qualitative research. Results: A total of 11 members in multidisciplinary care teams and 7 patients diagnosed as colorectal cancer, breast cancer, and lung cancer, or their families, were recruited in this study. The factors and timing of discontinuing anticancer treatment decisions were affected by age and different cancer characteristics. The “treatment efficacy and physical health status' were the most important factors. However, 'subjective feelings or psychological factors' and 'sociological or economic support' were both quite influential. The decision-making process for termination of anticancer treatment included: 'the content and skills of truth-telling by physicians', ' the transmission of patient's autonomous information', 'the crucial role-playing by medical assistants', 'seeking consensus', and 'the coping strategies”. Nice teamwork on truth-telling of disease and multidisciplinary care contributed to the decision on withholding anticancer remedies. While the providers of medical treatment, patients and families accepted that anticancer therapy was invalid, meaningless and the necessity of death, hospice care might be able to deliver. The reason for pursuing hospice care was to manage the problems from symptoms, to promote of comforts, and to deliver psychological and spiritual support. Early intervention of palliative care could help improving the quality of life of patients with advanced cancer. However, it is still difficult to implement in the acute ward at early stage. Conclusion: This study explored the decision-making process on withholding anticancer therapy and accepting hospice care in cancer patients with advanced cancer. The results hope to provide a useful reference in policy and practice, and a basis of research in the future. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T23:39:08Z (GMT). No. of bitstreams: 1 ntu-109-R05848014-1.pdf: 7224994 bytes, checksum: 02e1d81b06b9aadbeebcebda607064d6 (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 致謝 I
中文摘要 III Abstract V 目 錄 VII 表目錄 IX 圖目錄 XI 第一章 緒論 1 第一節 研究背景與動機 1 第二節 研究目的 3 第二章 文獻探討 4 第一節 癌症治療的趨勢與成效 4 第二節 癌症病人進行晚期抗癌治療之探討 6 第三節 癌症病人終止抗癌治療之探討 9 第四節 癌症病人接受安寧療護之探討 14 第五節 小結 18 第三章 研究方法 19 第一節 研究設計與架構 19 第二節 研究機構與情境 20 第三節 研究對象與材料 21 第四節 研究工具 23 第五節 質性訪談資料處理與分析 24 第六節 研究嚴謹性與研究倫理 25 第四章 研究結果 26 第一節 受訪人員代號與背景資料 26 第二節 癌症病人終止抗癌治療決策之觀點 30 第三節 癌症病人接受安寧療護決策之觀點 48 第四節 終止抗癌與介入安寧的挑戰與困境 58 第五章 討論 82 第一節 研究方法與受訪者背景之討論 82 第二節 癌症病人終止抗癌治療決策因素與困境 84 第三節 癌症病人接受安寧療護決策因素與困境 91 第四節 研究限制 94 第六章 結論與建議 95 第一節 結論 95 第二節 建議 95 參考文獻 98 附錄一 IRB審查通過證明 111 附錄二 受訪者同意書 113 附錄三 訪談大綱(主責醫療團隊) 120 附錄四 訪談大綱(病人或家屬) 121 | |
dc.language.iso | zh-TW | |
dc.title | 探索癌症病人終止抗癌治療及接受安寧療護決策之觀點 | zh_TW |
dc.title | Exploring Views of Decision-Making on Withhold of Anticancer Therapy and Acceptance of Hospice Care in Cancer Patients | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 邱秀渝(Shiuyu Chiu Katie Lee),邱仲?(Jeng-Fong Chiou) | |
dc.subject.keyword | 終止抗癌治療,接受安寧療護,質性訪談,NVivo, | zh_TW |
dc.subject.keyword | withhold of anticancer therapy,acceptance of hospice care,qualitative interview method,NVivo, | en |
dc.relation.page | 121 | |
dc.identifier.doi | 10.6342/NTU202000328 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2020-02-19 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 健康政策與管理研究所 | zh_TW |
顯示於系所單位: | 健康政策與管理研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-109-1.pdf 目前未授權公開取用 | 7.06 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。